N-propan-2-yl-4,5-dihydro-1H-imidazol-2-amine | 871128-07-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: N-propan-2-yl-4,5-dihydro-1H-imidazol-2-amine
• CAS: 871128-07-3
• 化学式: C₆H₁₃N₃
• 分子量: 127.189
• InChiKey: MEWFQWCZHSJROJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  36.4
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  乙二胺 、 N,N'-二异丙基碳二亚胺 在 [ς:η1:η5-(OCH2)(Me2NCH2)C2B9H9]Ti-(NMe2) 作用下， 以 甲苯 为溶剂， 反应 48.0h， 以70%的产率得到N-propan-2-yl-4,5-dihydro-1H-imidazol-2-amine
  参考文献：
  名称：

  二酰胺/三胺和碳二亚胺催化钛酰胺催化合成环胍

  摘要：

  报道了钛碳碳烷单酰胺催化的由市售二胺/三胺和碳二亚胺一步合成单/双环胍。还提出了反应机理。

  DOI：

  10.1021/ol201752e

文献信息

• Uniform, Functionalized, Cross-Linked Nanostructures for Monitoring pH
  申请人：Wooley Karen L.

  公开号：US20150346099A1

  公开（公告）日：2015-12-03

  Described herein are optical agents, including compositions, preparations and formulations, for monitoring the pH of a fluid. Optical agents described herein include photonic nanostructures and nanoassemblies including supramolecular structures, such as shell cross-linked micelles, that incorporate at least one linking group comprising one or more photoactive moieties that provide functionality as exogenous agents for a range of pH monitoring applications. Optical agents described herein comprise supramolecular structures having linking groups imparting useful optical and structural functionality. In an embodiment, for example, the presence of linking groups function to covalently cross link polymer components to provide a cross-linked shell stabilized supramolecular structure, and also impart useful optical functionality, for example by functioning as a fluorophore.

  本文描述了光学试剂，包括用于监测流体pH的组成物、制剂和配方。这里描述的光学试剂包括光子纳米结构和纳米组装体，包括超分子结构，如壳交联胶囊，其包含至少一个含有一个或多个光活性基团的连接基团，作为外源试剂在各种pH监测应用中发挥功能。这里描述的光学试剂包括具有连接基团的超分子结构，赋予有用的光学和结构功能。例如，在一个实施例中，连接基团的存在可以通过共价交联聚合物组分来提供一个交联壳稳定的超分子结构，并且还可以赋予有用的光学功能，例如作为荧光团。
• Efficient Synthesis of 2‐(<i>N</i>‐Substituted)‐2‐imidazolines and 2‐(<i>N</i>‐Substituted)‐1,4,5,6‐tetrahydropyrimidines
  作者：Wai Ming Kan、Shih‐Hsun Lin、Ching‐Yuh Chern

  DOI：10.1080/00397910500213005

  日期：2005.10.1

  Abstract A general method for the preparation of 2‐(N‐Substituted)‐2‐imidazolines and 2‐(N‐Substituted)‐1,4,5,6‐tetrahydropyrimidines is described. These heterocycles can be synthesized from their respective anilines with 2‐chloro‐2‐imidazoline or 2‐chloro‐1,4,5,6‐tetrahydropyrimidine, generated in situ from imidazolidin‐2‐one and tetrahydropyrimidin‐2(1H)‐one activated by dimethyl chlorophosphate

  摘要描述了制备 2-(N-取代)-2-咪唑啉和 2-(N-取代)-1,4,5,6-四氢嘧啶的一般方法。这些杂环可以由它们各自的苯胺与 2-氯-2-咪唑啉或 2-氯-1,4,5,6-四氢嘧啶合成，由咪唑啉-2-酮和四氢嘧啶-2(1H)-酮原位生成氯磷酸二甲酯活化，收率良好。
• METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS
  申请人：Fang Wenkui K.

  公开号：US20090306161A1

  公开（公告）日：2009-12-10

  Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, both acute and chronic.

  本文描述了一种治疗受试者疾病或病症的化合物和方法，方法是通过向受试者施用含有有效量α-肾上腺素调节剂的药物组合物。这些化合物和方法还可用于缓解各种类型的疼痛，包括急性和慢性疼痛。
• Beta Amino Acid Derivatives as Integrin Antagonists
  申请人：Saint Louis University

  公开号：US20140038910A1

  公开（公告）日：2014-02-06

  Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.

  本文揭示了一种新型药物，它们可用作整合素受体拮抗剂，介导血管生成和纤维化的病理过程，并且因此可用于制备药物组合物和治疗通过抑制或拮抗这些整合素介导的疾病的方法。这些新型药物包括以下公式中的药物：其中变量在此定义。还提供了包含这些药物的制药组合物、试剂盒和制品。还提供了用于制造药物的方法和中间体以及使用药物的方法。
• ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE
  申请人：The Regents of the University of California

  公开号：US20160264566A1

  公开（公告）日：2016-09-15

  Provided herein, inter alia, are methods and compositions for inhibiting αvβ1 integrin and for treating fibrosis.

  本文提供了抑制αvβ1整合素和治疗纤维化的方法和组合物等内容。